EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

TREM2 in Neurodegenerative Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting

Hyewon Yang, Danyeong Kim iD, YoungSoon Yang iD, Eva Bagyinszky iD, Seong Soo A An iD

International Journal of Molecular Sciences · 22.07.2025 · 26 (15) · 7057

DOI: 10.3390/ijms26157057 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.07.2025. Verfasst von Hyewon Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bionano Technology, Gachon University, Seongnam 13120, Republic of Korea. Hauptthemen laut MEDLINE: Receptors, Immunologic, Membrane Glycoproteins, Neurodegenerative Diseases, Mutation. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Basic Science Research Program through the National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TREM2 (triggering receptor expressed on myeloid cells 2) is a membrane-bound receptor primarily expressed on microglia in the central nervous system (CNS). TREM2 plays a crucial role in regulating immune responses, phagocytosis, lipid metabolism, and inflammation. Mutations in the TREM2 gene have been linked to various neurodegenerative diseases, including Alzheimer’s disease (AD), frontotemporal dementia (FTD), Parkinson’s disease (PD), and Nasu–Hakola disease (NHD). These mutations are suggested to impair microglial activation and reduce the ability to clear amyloid aggregates, leading to exacerbated neuroinflammatory responses and accelerating disease progression. This review provides an overview of TREM2 structure, functions, and known pathogenic variants—including Arg47His, Arg62His, His157Tyr, Tyr38Cys, and Thr66Met. Furthermore, the molecular and cellular consequences of TREM2 mutations are introduced, such as impaired ligand binding, altered protein folding and trafficking, enhanced TREM2 shedding, and dysregulated inflammatory signaling. We also highlight recent advances in therapeutic strategies aimed at modulating TREM2 signaling. These include monoclonal antibodies (e.g., AL002, CGX101), small molecule agonists, and gene/cell-based therapies that seek to restore microglial homeostasis, enhance phagocytosis, and reduce neuroinflammation. While these approaches show promise in in vivo/in vitro studies, their clinical translation may be challenged by disease heterogeneity and mutation-specific responses. Additionally, determining the appropriate timing and precise dosing will be essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicMembrane GlycoproteinsNeurodegenerative DiseasesMutationHumansAnimalsMicroglia

Stichwörter der Autor:innen

Alzheimer’s diseaseNasu-Hakola diseaseTREM2frontotemporal dementiamutationtherapy

Substanzen

Receptors, ImmunologicTREM2 protein, humanMembrane Glycoproteins

Autor:innen und Institutionen

  • Department of Bionano Technology, Gachon University, Seongnam 13120, Republic of Korea.
  • Department of Neurology, Veterans Medical Research Institute, Veterans Health Service Medical Center, Seoul 05368, Republic of Korea.
  • Department of Neurology, Soonchunhyang University Hospital, Cheonan 31151, Republic of Korea.
  • Department of Industrial and Environmental Engineering, Graduate School of Environment, Gachon University, Seongnam 13120, Republic of Korea.

ORCID-Profile: Danyeong Kim, YoungSoon Yang, Eva Bagyinszky, Seong Soo A An

Förderung

  • National Research Foundation of Korea
  • Basic Science Research Program through the National Research Foundation of Korea (NRF)

Zitieren

APA

Yang, H., Kim, D., Yang, Y., Bagyinszky, E., & An, S. S. A. (2025). TREM2 in Neurodegenerative Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting. International Journal of Molecular Sciences, 26(15), 7057. https://doi.org/10.3390/ijms26157057

Vancouver

Yang H, Kim D, Yang Y, Bagyinszky E, An SSA. TREM2 in Neurodegenerative Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting. International Journal of Molecular Sciences. 2025;26(15):7057. doi:10.3390/ijms26157057

BibTeX
@article{Yang2025,
  author = {Yang, Hyewon and Kim, Danyeong and Yang, YoungSoon and Bagyinszky, Eva and An, Seong Soo A},
  title = {TREM2 in Neurodegenerative Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {15},
  pages = {7057},
  doi = {10.3390/ijms26157057}
}
Kostenlos starten →